Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- BMS Files Repotrectinib in Japan for ROS1-Positive NSCLC
October 26, 2023
- With Wholesalers Narrowed Down, Hospitals Face Squeezed Discounts for GSK Products
October 25, 2023
- Yakult to Divest Cancer Portfolio to Takata, Pull Plug on New Development
October 25, 2023
- Roche Group, Biogen Reach Settlement over Actemra Biosimilar
October 25, 2023
- Tecentriq Plus Avastin, Chemo Hit Goal in Extensive-Stage SCLC
October 25, 2023
- Ono, Turbine Ink Research Collab in Hunt for Oncology Targets
October 25, 2023
- Prostate Cancer Med Orgovyx Approved in Canada: Sumitomo
October 25, 2023
- Sawai Fudged Quality Tests of Gastritis Drug for 8 Years, Awaiting Penalty Decision
October 24, 2023
- Janssen Files PAH Fixed-Dose Combo Drug in Japan
October 24, 2023
- Enhertu Gets EU Nod for NSCLC, Triggers US$75 Million Milestone
October 24, 2023
- Pfizer Japan Recalling Docetaxel IV Infusion 20 mg/2 mL
October 23, 2023
- Daiichi Sankyo, Merck in Global ADC Deal Worth Up to US$22 Billion
October 23, 2023
- Myfembree Gets Canada Nod for Uterine Fibroid, Endometriosis
October 23, 2023
- Takeda’s Adcetris Approved in Europe for 7th Indication
October 23, 2023
- Medicon, Mucodyne among Drugs Subject to MHLW’s Ramp-Up Request
October 20, 2023
- Oncology, Cell & Gene Therapies Key Priorities for Bayer Co.Labs: Global Head
October 20, 2023
- Kyowa Kirin Set to Gain Tens of Billions of Yen in Sales from Orchard Acquisition
October 20, 2023
- Takeda to Pay 130 Million Euro to Settle Tax Row over Shire-AbbVie Breakup Fee
October 19, 2023
- Takeda’s 1st Cell Therapy Alofisel Misses Goal in Key PIII Study
October 19, 2023
- Diazepam Nasal Spray Shows Efficacy in PIII Interim Analysis: Aculys
October 19, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…